Table 2.
Analyses of the associations between serological variables and survival status in 160 critically ill ILD patients.
| Variables | survivors (n = 58) | nonsurvivors (n = 102) | P value |
|---|---|---|---|
| WBC (*109) | 10.0 (7.5–12.0) | 10.1 (7.0–13.8) | 0.619 |
| N (%) | 85.5 (72.6–89.4) | 88.3 (80.1–92.3) | 0.016 |
| Hb (g/l) | 124.5 (107.0–137.3) | 125.0 (116.8–142.0) | 0.558 |
| PLT (*109) | 218.0 (181.3–284.0) | 176.5 (121.0–259.3) | 0.002 |
| L (*109) | 0.97 (0.66–1.39) (n = 53) | 0.73 (0.45–1.13) (n = 75) | 0.021 |
| CD4+ (*106) | 315.5 (186.8–486.5) (n = 54) | 189.0 (106.0–368.0) (n = 77) | 0.004 |
| CD8+ (*106) | 270.5 (148.3–474.3) (n = 54) | 183.0 (91.5–388.5) (n = 77) | 0.040 |
| PCT (ng/ml) | 0.05 (0.02–0.12) (n = 45) | 0.08 (0.04–0.27) (n = 66) | 0.053 |
| CRP (mg/l) | 27.6 (6.9–59.9) (n = 57) | 47.8 (9.4–94.6) (n = 101) | 0.048 |
| IgA (g/l) | 2.6 (1.8–3.3) (n = 53) | 2.7 (2.0–3.8) (n = 89) | 0.546 |
| IgG (g/l) | 12.2 ± 4.2(n = 53) | 12.3 ± 4.6(n = 89) | 0.960 |
| IgM (g/l) | 1.2 (0.9–1.9) (n = 53) | 1.0 (0.7–1.4) (n = 89) | 0.013 |
| IgE (IU/ml) | 102.0 (44.0–222.0) (n = 51) | 100.0 (60.0–167.5) (n = 73) | 0.974 |
| AST (U/L) | 21.3 (15.5–27.2) (n = 57) | 27.5 (19.4–45.6) (n = 101) | 0.007 |
| ALT (U/L) | 22.7 (13.8–36.3) (n = 57) | 24.9 (17.2–40.1) (n = 101) | 0.212 |
| LDH (U/L) | 343.0 (279.0–438.0) (n = 57) | 456.0 (310.5–603.0) (n = 101) | 0.001 |
| Scr (umol/l) | 57.5 (49.8–73.7) | 57.0 (46.7–70.2) | 0.306 |
| CYF 21-1 (ng/ml) | 5.2 (3.9–8.0) (n = 51) | 11.0 (7.4–16.6) (n = 89) | 0.000 |
| NSE (ng/ml) | 15.9 (12.6–22.8) (n = 51) | 26.5 (18.7–38.3) (n = 89) | 0.000 |
| CEA (ng/ml) | 3.1 (2.2–4.2) (n = 51) | 6.7 (3.1–12.2) (n = 89) | 0.000 |
| PaO2 (mmHg) | 74.0 (63.0–89.0) (n = 55) | 67.0 (54.8–79.0) (n = 101) | 0.014 |
| PaCO2 (mmHg) | 37.4 (32.5–43.5) (n = 55) | 35.2 (30.6–40.0) (n = 100) | 0.106 |
| P/F (mmHg) | 230.4 ± 83.1(n = 55) | 173.2 ± 79.8(n = 101) | 0.000 |
| ANA | 29 (54.7%) (n = 53) | 34 (37.8%) (n = 90) | 0.049 |
| ENA | 32 (60.4%) (n = 53) | 44 (48.9%) (n = 90) | 0.184 |
| ANCA | 5 (9.4%) (n = 53) | 9 (10.0%) (n = 90) | 0.912 |
| G test | 4 (8.2%) (n = 49) | 19 (27.5%) (n = 69) | 0.009 |
| GM test | 1 (2.0%) (n = 49) | 6 (8.6%) (n = 70) | 0.136 |
Variables: WBC White blood cell count; N Percentage of neutrophil; Hb Hemoglobin; PLT Platelet; L Blood lymphocyte count; CD4 + CD4 + lymphocytes; CD8 + CD8 + lymphocytes; PCT Procalcitonin; CRP C-reactive protein; IgA Immunoglobulin A; IgG Immunoglobulin G; IgM Immunoglobulin M; Ig E Immunoglobulin E; AST Aspartate aminotransferase; ALT Alanine aminotransferase; LDH Lactate dehydrogenase; Scr Serum creatinine; CYF 21-1 Cytokeratin 21-1; NSE Neuron specific enolase; CEA Carcinoembryonic antigen; PaO2 Oxygen partial pressure; PaCO2 Carbon dioxide partial pressure; P/F Oxygenation index; ANA Autoantibody ANA positive; ENA Autoantibody ENA positive; ANCA Anti-neutrophil cytoplasmic antibody positive; G test Fungal glucan test positive; GM test Galactomannan test positive.